
Supplementary Figure 1. Quality of included randomized controlled trials based on the

Cochrane Collaboration's tool for assessing risk of bias.



Supplementary Figure 2. Meta-analysis of changes in IBS-Severity Scoring System (IBS-SSS)

compared with baseline at 4-, 8- and 24-weeks treatment points in fecal microbiota

transplantation (FMT) versus control.

A. 4 weeks

	FMT			Control				Mean Difference	Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Random, 95% CI			
Aroniadis, 2018	67.12	122.18	24	70.81	121.93	24	22.0%	-3.69 [-72.75, 65.37]			-		
Halkjær, 2018	65	91.52	25	120.92	112.19	26	24.9%	-55.92 [-112.02, 0.18]	•				
Holster, 2019	50.06	89.88	8	28.12	33.89	8	22.6%	21.94 [-44.62, 88.50]		82			
Johnsen, 2018	106.39	62.22	55	48.6564	63.81	28	30.5%	57.73 [28.94, 86.53]					
Total (95% CI)			112			86	100.0%	7.84 [-48.10, 63.78]					
Heterogeneity: Tau ² = 2454.82; Chi ² = 13.53, df = 3 (P = 0.004); I ² = 78% Test for overall effect: Z = 0.27 (P = 0.78)										-50	Ö	50	100

B. 8 weeks

	FMT			Control				Mean Difference	Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV,	Fixed, 95%	CI	
Aroniadis, 2018	72.28	125.9	24	66.15	125.56	24	67.3%	6.13 [-65.01, 77.27]					-
Holster, 2019	55.26	51.73	8	29.4	137.93	8	32.7%	25.86 [-76.22, 127.94]	_			-	
Total (95% CI)			32			32	100.0%	12.58 [-45.78, 70.94]					
Heterogeneity: $Chi^2 = 0.10$, df = 1 (P = 0.76); l ² = 0% Test for overall effect: Z = 0.42 (P = 0.67)									-100	-50	Ö	50	100

C. 24 weeks

	FN	IT		Control				Mean Difference	Mean Difference		
Study or Subgroup	Mean SD Total			Mean	Mean SD Total W		Weight	IV, Random, 95% CI	IV, Random, 95% CI		
Aroniadis, 2018	64.69	124.28	24	145.86	123.26	24	22.9%	-81.17 [-151.20, -11.14]	< ■		
Halkjær, 2018	41.86	84.24	25	115.57	128.83	26	24.2%	-73.71 [-133.23, -14.19]	• •		
Holster, 2019	36.56	59.23	8	47.6	34.41	8	25.6%	-11.04 [-58.51, 36.43]			
Johnsen, 2018	108.0390722	61.48	55	39.5842268	63.82	28	27.3%	68.45 [39.77, 97.14]			
Total (95% CI)			112			86	100.0%	-20.62 [-97.30, 56.07]			
Heterogeneity: Tau ² = 5398.67; Chi ² = 30.14, df = 3 (P < 0.00001); I ² = 90% Test for overall effect: Z = 0.53 (P = 0.60)										50 100	

studies	Desi gn	Limitations	Inconsist ency	Indirect ness	Impreci sion	Publicatio n Bias	Quali	Importa nce			
improve			weeks								
4		Autologous FMT as placebo in some studies	Very serious	Not serious	Serious	Possible	⊕O OO Very LOW	Critical			
Changes	Changes in IBS-SSS at 4, 8, 12 and 24 weeks compared to baseline in FMT vs. Control										
2-4	RCT	Autologous FMT as placebo in some studies	Very serious	Not serious	Serious	Possible	⊕O OO Very LOW	Critical			
Change	Changes in IBS-QOL at 12 weeks compared to baseline in FMT vs. Control										
3		Autologous FMT as placebo in some studies	Very serious	Not serious	Serious	Possible	⊕O OO Very LOW	Critical			

Supplementary table 1. Level of evidence based on GRADE